Sexual Health · Placeholder catalog data
PT-141
Also known as Bremelanotide
A cyclic heptapeptide analog of α-MSH acting at central melanocortin receptors. Approved as Vyleesi® for hypoactive sexual desire disorder; widely studied in melanocortin pathway research.
130 credits
Paid from your credit pool at checkout. Bulk quantities discount automatically.
Available variants
Pricing and fulfillment information is placeholder data.
| Amount | SKU | Credits | MSRP | Availability | Margin estimate |
|---|---|---|---|---|---|
| 10 mg | PTS-PT1-10 | 26 credits | $49 | Ready | 47% estimate |
Margin estimate treats 1 credit as $1 and compares estimated wholesale credit cost with placeholder MSRP. It excludes shipping, taxes, and other costs.
Buy more, save more
Quantity breaks apply per line item and are deducted automatically at checkout.
| Quantity per line | Discount | Example (10 mg unit) |
|---|---|---|
| 10+ units | 5% off | 10 × 26 credits → 247 credits |
| 25+ units | 10% off | 25 × 26 credits → 585 credits |
| 50+ units | 15% off | 50 × 26 credits → 1,105 credits |
| 100+ units | 20% off | 100 × 26 credits → 2,080 credits |
Specifications
- CAS
- 189691-06-3
- Formula
- C50H68N14O10
- Molecular weight
- 1025.18 g/mol
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Purity
- ≥99%
- Appearance
- White to off-white lyophilized powder
- Storage
- Store lyophilized at 2–8 °C, protected from light and moisture
Quality record
COA status
COA listedLot PTS-PT1-2607
Placeholder reference. Verify the active lot before ordering.
Research background
PT-141, known generically as Bremelanotide, is a cyclic heptapeptide derivative of α-melanocyte stimulating hormone. It acts as a non-selective agonist at melanocortin receptors with preferential activity at MC3R and MC4R in published pharmacology literature.
Originally investigated as a sunless tanning agent, subsequent research identified central effects on sexual motivation and arousal in preclinical models and clinical trials. The molecule is FDA-approved as Vyleesi® for the treatment of premenopausal hypoactive sexual desire disorder.
Supplied as a research-grade reference peptide for investigation of central melanocortin signaling. Not supplied for therapeutic use.
Mechanism: Literature describes PT-141 as a non-selective melanocortin receptor agonist with preferential MC3R/MC4R activity, engaging central pathways associated with sexual motivation.
Research use only
For research use only. Not for human or veterinary use.